New Psychoactive Substances

National Roundtable on the Completed Prevalence Study on New Psychoactive Substances

Nur-Sultan, Kazakhstan,
We invite specialists of the Ministry of Health of the Republic of Kazakhstan, the Ministry of Internal Affairs of the Republic of Kazakhstan, the Kazakh Scientific Center of Dermatology and Infectious Diseases, representatives of the UNODC, UNAIDS, non-governmental organizations, heads and doctors of regional mental health Centers.

Another Milestone for Kenya: Launch of the National Standard on Management of Persons with Substance Use Disorders

According to the International Standards for the Treatment of Drug Use Disorders (2020), the use of psychoactive drugs or narcotic drugs and psychotropic substances without medical supervision is associated with significant health risks. Backing this up the World Drug Report 2022 indicates that around 284 million people aged 15-64 used drugs worldwide in 2022, a 26 percent increase over the previous decade. Unfortunately, this translates to an accelerated impact on public health, drug use disorders

Risks, harms and clinical implications of Novel Psychoactive Substances


As part for the new webinar series of International Society for the Study of Emerging Drugs (ISSED), we are pleased to invite you to attend a workshop on “Health Risks, Harms and Clinical Implications of Novel Psychoactive Substances” facilitated by Prof. Giuseppe Bersani and Prof. Owen Bowden-Jones.